Genetically modified Lactococcus lactis:: novel tools for drug delivery

被引：7
|
作者：
Steidler, L [1 ]
Vandenbroucke, K
机构：
[1] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland
[2] Univ Ghent, B-9000 Ghent, Belgium
[3] Flanders Interuniv, Inst Biotechnol, Dept Mol Biomed Res, Ghent, Belgium
来源：
INTERNATIONAL JOURNAL OF DAIRY TECHNOLOGY | 2006年 / 59卷 / 02期
关键词：
biological containment; cytokine; drug delivery; GMO therapeutics; Lactococcus lactis; thymidylate synthase;
D O I：
10.1111/j.1471-0307.2006.00255.x
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
The dairy bacterium Lactococcus lactis can be genetically engineered to secrete bioactive cytokines. This enabled the development of an entirely novel drug delivery system: topical and active delivery of therapeutic proteins by genetically modified micro-organisms. In mice, intestinal inflammation can be successfully treated with interleukin-10- (IL-10) or trefoil factor-secreting L. lactis. In human application, biological containment is guaranteed by exchange of the gene encoding thymidylate synthase for IL-10. The recombinant strain is now absolutely dependent on exogenous thymidine. Thymidine starvation will irreversibly lead to 'thymidine-less death' induction. This accomplishment has opened applications in human medicine.
引用
收藏
页码：140 / 146
页数：7
相关论文
共 50 条
  • [1] Therapeutic drug delivery by genetically modified Lactococcus lactis
    Steidler, Lothar
    Rottiers, Pieter
    INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS, 2006, 1072 : 176 - 186
  • [2] In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Steidler, L
    ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 2002, 82 (1-4): : 323 - 331
  • [3] In situ delivery of cytokines by genetically engineered Lactococcus lactis
    Lothar Steidler
    Antonie van Leeuwenhoek, 2002, 82 : 323 - 331
  • [4] Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
    Steidler, L
    Neirynck, S
    Huyghebaert, N
    Snoeck, V
    Vermeire, A
    Goddeeris, B
    Cox, E
    Remon, JP
    Remaut, E
    NATURE BIOTECHNOLOGY, 2003, 21 (07) : 785 - 789
  • [5] Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
    Lothar Steidler
    Sabine Neirynck
    Nathalie Huyghebaert
    Veerle Snoeck
    An Vermeire
    Bruno Goddeeris
    Eric Cox
    Jean Paul Remon
    Erik Remaut
    Nature Biotechnology, 2003, 21 : 785 - 789
  • [6] Genetically Modified Lactococcus lactis for Delivery of Human Interleukin-10 to Dendritic Cells
    Huibregtse, Inge L.
    Zaat, Sebatian A.
    Kapsenberg, Martien L.
    da Silva, Maria A. Sartori
    Peppelenbosch, Maikel P.
    van Deventer, Sander J. H.
    Braat, Henri
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2012, 2012
  • [7] Induction of Natural Competence in Genetically-modified Lactococcus lactis
    Mulder, Joyce
    Wels, Michiel
    Kuipers, Oscar P.
    Kleerebezem, Michiel
    Bron, Peter A.
    BIO-PROTOCOL, 2018, 8 (13):
  • [8] Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice
    Vandenbroucke, K
    Hans, W
    Van Huysse, J
    Neirynck, S
    Demetter, P
    Remaut, E
    Rottiers, P
    Steidler, L
    GASTROENTEROLOGY, 2004, 127 (02) : 502 - 513
  • [9] In situ delivery of cytokines at mucosal surfaces by genetically engineered Lactococcus lactis
    Steidler, L
    NOVEL PROCESSES AND CONTROL TECHNOLOGIES IN THE FOOD INDUSTRY, 2001, 338 : 179 - 196
  • [10] Modulation of Gut-Associated Lymphoid Tissue Functions with Genetically Modified Lactococcus lactis
    Rottiers, Pieter
    De Smedt, Tim
    Steidler, Lothar
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2009, 28 (06) : 465 - 486
12345